AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7861825 — intervention group
Group type: EXPERIMENTAL
Intervention: AVIVA - a talking computer that assesses health risk, gives priorities for risk reduction, discusses risk reduction methods, and refers callers to additional information.
Number of subjects: 96
Study 7861825 — intervention group
Group type: COMPARATOR
Intervention: Health information from magazines, television, or health professionals.
Number of subjects: 96
Study 2387667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg twice daily for 4 weeks)
Number of subjects: 13
Study 2387667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6122232 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg propoxyphene napsylate (PN) in two divided doses
Number of subjects: 0
Study 6122232 — intervention group
Group type: COMPARATOR
Intervention: 10 mg methadone
Number of subjects: 0
Study 6122232 — intervention group
Group type: COMPARATOR
Intervention: 20 mg methadone
Number of subjects: 0
Study 6122232 — intervention group
Group type: COMPARATOR
Intervention: Placebo methadone
Number of subjects: 0
Study 31678446 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoscopeRobot
Number of subjects: 30
Study 31678446 — intervention group
Group type: COMPARATOR
Intervention: Control (without EndoscopeRobot)
Number of subjects: 30
Study 30773772 — intervention group
Group type: EXPERIMENTAL
Intervention: Malted sorghum‐based porridge (MSBP)
Number of subjects: 220
Study 30773772 — intervention group
Group type: COMPARATOR
Intervention: Extruded maize and soy micronutrient fortified blend (CSB+)
Number of subjects: 220
Study 28751226 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐lasting tDCS (20 min) during training
Number of subjects: 80
Study 28751226 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐lasting tDCS (10 min-25 min break-10 min) one day before training
Number of subjects: 80
Study 28751226 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐lasting tDCS one day before training
Number of subjects: 80
Study 28751226 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 80
Study 28751226 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF Met allele presence
Number of subjects: 80
Study 25770879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel (0.015% once daily for 3 days for face/scalp; 0.05% once daily for 2 days for trunk/extremities)
Number of subjects: 1005
Study 25770879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Number of subjects: 1005
Study 25770879 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1005
Study 25199059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mepolizumab (75 mg every 4 weeks for 32 weeks)
Number of subjects: 576
Study 25199059 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mepolizumab (100 mg every 4 weeks for 32 weeks)
Number of subjects: 576
Study 25199059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 21114680 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (non-surgical periodontal therapy)
Number of subjects: 60
Study 21114680 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 60
Study 19526589 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously weekly)
Number of subjects: 0
Study 19526589 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (3 million U subcutaneously 3x weekly, escalating to 18 MU)
Number of subjects: 0
Study 17511767 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day for 4 weeks increased to 120 mg/day for 8 weeks
Number of subjects: 306
Study 17511767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 15370730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (group A)
Number of subjects: 20
Study 15370730 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 20
Study 16493377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet therapy with antioxidant and ω-3 supplementation
Number of subjects: 40
Study 16493377 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric balanced diet therapy
Number of subjects: 40
Study 9190351 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 248
Study 9190351 — intervention group
Group type: COMPARATOR
Intervention: Dilation and curettage (D&C)
Number of subjects: 248
Study 8352625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity direct current (300 to 600 microA)
Number of subjects: 74
Study 8352625 — intervention group
Group type: COMPARATOR
Intervention: Sham instrument (placebo group)
Number of subjects: 74
Study 3610329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of 1 g cefpirome
Number of subjects: 10
Study 3610329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) injection of 1 g cefpirome
Number of subjects: 10
Study 3610329 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) and Intramuscular (i.m.) injections of 1 g cefpirome
Number of subjects: 10
Study 31509850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 175
Study 31574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection before 24 weeks gestation
Number of subjects: 1628
Study 31574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria positive only before week 24
Number of subjects: 1628
Study 31574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria before 24 weeks gestation
Number of subjects: 1628
Study 28282005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty
Number of subjects: 124
Study 28282005 — intervention group
Group type: COMPARATOR
Intervention: Nonomentoplasty
Number of subjects: 124
Study 25352437 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RDA (1.5 g·kg(‐1)·day(‐1))
Number of subjects: 20
Study 25352437 — intervention group
Group type: COMPARATOR
Intervention: 1RDA (0.8 g·kg(‐1)·day(‐1))
Number of subjects: 20
Study 23683639 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's groups
Number of subjects: 26262
Study 23683639 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 26262
Study 21310040 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal bronchodilation
Number of subjects: 40
Study 21310040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (undilated condition)
Number of subjects: 40
Study 19342506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexacerfont 25 mg qd
Number of subjects: 39
Study 19342506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexacerfont 100 mg qd
Number of subjects: 39
Study 19342506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16478794 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin chemotherapy
Number of subjects: 54
Study 15270741 — intervention group
Group type: EXPERIMENTAL
Intervention: Family unit treatment (all infected family members treated)
Number of subjects: 50
Study 15270741 — intervention group
Group type: COMPARATOR
Intervention: Index case treatment (index case only treated)
Number of subjects: 50
Study 10985630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests at 1, 3, and 7 cm distance from potassium dichromate patches
Number of subjects: 589
Study 10985630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests at 1 cm distance from potassium dichromate patches
Number of subjects: 589
Study 10985630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests
Number of subjects: 589
Study 9087680 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg)
Number of subjects: 8
Study 9087680 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial drugs (AMDs) prescribed to hospitalized children
Number of subjects: 1000
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 1000
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin
Number of subjects: 1000
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pharmacotherapeutic categories
Number of subjects: 1000
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 1000
Study 8364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group (1-year group)
Number of subjects: 1000
Study 3511372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide plus low-dose prednisone
Number of subjects: 107
Study 3511372 — intervention group
Group type: COMPARATOR
Intervention: High-dose oral prednisone alone
Number of subjects: 107
Study 3293827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg body weight)
Number of subjects: 200
Study 3293827 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg)
Number of subjects: 200
Study 3293827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Number of subjects: 200
Study 3293827 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg) + sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Number of subjects: 200
Study 3293827 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine alone
Number of subjects: 200
Study 31222778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led assessment and care planning intervention for frail older people
Number of subjects: 60
Study 31222778 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care for frailty
Number of subjects: 60
Study 29066876 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training (IMT)
Number of subjects: 40
Study 29066876 — intervention group
Group type: COMPARATOR
Intervention: Expiratory muscle training (EMT)
Number of subjects: 40
Study 25138579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg (D/T group)
Number of subjects: 248
Study 25138579 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin OCAS 0.4 mg only (T group)
Number of subjects: 248
Study 22802301 — intervention group
Group type: EXPERIMENTAL
Intervention: Logo-autobiography (LA)
Number of subjects: 40
Study 22802301 — intervention group
Group type: COMPARATOR
Intervention: Control group (with antidepressants)
Number of subjects: 40
Study 21791883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VerifyNow P2Y12 (PRU) and Aspirin (ARU) testing
Number of subjects: 716
Study 21791883 — intervention group
Group type: COMPARATOR
Intervention: Tertiles of ARU
Number of subjects: 716
Study 21791883 — intervention group
Group type: COMPARATOR
Intervention: Tertiles of PRU
Number of subjects: 716
Study 21791883 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of the sum of ARU and PRU tertiles
Number of subjects: 716
Study 18343158 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 21
Study 18343158 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered Tennis Elbow (RTE)
Number of subjects: 21
Study 18343158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis Elbow (TE)
Number of subjects: 21
Study 17361920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day orally
Number of subjects: 8113
Study 17361920 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy (bicalutamide)
Number of subjects: 8113
Study 17361920 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant bicalutamide
Number of subjects: 8113
Study 17361920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study 15293174 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up by a nurse researcher
Number of subjects: 238
Study 11153668 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)
Number of subjects: 171
Study 9370179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonisotopic (cold) iothalamate measured by capillary electrophoresis
Number of subjects: 0
Study 9370179 — intervention group
Group type: COMPARATOR
Intervention: Standard clearance using 125I‐iothalamate
Number of subjects: 0
Study 8421475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 2877131 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone substitution therapy (TTS)
Number of subjects: 7
Study 29178769 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing agents (five commercially available agents applied according to manufacturers' instructions)
Number of subjects: 64
Study 29178769 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing agents (five commercially available agents)
Number of subjects: 64
Study 26331280 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention using the Achievable Benchmark of Care (ABC) method
Number of subjects: 2199
Study 26331280 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 2199
Study 25100892 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.5 mg/kg)
Number of subjects: 8
Study 25100892 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (CHO) (1 g/kg)
Number of subjects: 8
Study 25100892 — intervention group
Group type: COMPARATOR
Intervention: Caffeine + Maltodextrin
Number of subjects: 8
Study 22888676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380) consumed for 3 weeks
Number of subjects: 0
Study 22888676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380)
Number of subjects: 0
Study 19250082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ICD
Number of subjects: 57
Study 19250082 — intervention group
Group type: EXPERIMENTAL
Intervention: Max TVAR
Number of subjects: 57
Study 19250082 — intervention group
Group type: COMPARATOR
Intervention: Patients without ICD
Number of subjects: 57
Study 17584513 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-2000 formula (discriminant function involving IGF-I and P-III-P)
Number of subjects: 0
Study 17584513 — intervention group
Group type: EXPERIMENTAL
Intervention: Kreischa formula (discriminant function involving IGF-I, P-III-P, and IGFBP-3)
Number of subjects: 0
Study 15211018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistive training
Number of subjects: 55
Study 15211018 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparisons)
Number of subjects: 55
Study 12398172 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermaseal Plus sealer with ED Primer (Group A)
Number of subjects: 86
Study 12398172 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermaseal Plus sealer without ED Primer (Group B)
Number of subjects: 86
Study 12398172 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F with ED Primer (Group C)
Number of subjects: 86
Study 12398172 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F without ED Primer (Group D)
Number of subjects: 86
Study 12398172 — intervention group
Group type: COMPARATOR
Intervention: Negative control (entire root coated with wax)
Number of subjects: 86
Study 12398172 — intervention group
Group type: COMPARATOR
Intervention: Positive control (obturated with only a fitted master cone)
Number of subjects: 86
Study 10534516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy, 3 x 10(6) U s.c., three times a week (post-HD)
Number of subjects: 19
Study 10534516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 19
Study 10534516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 8869017 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3
Number of subjects: 60
Study 8869017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2270581 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg OTC three times/day
Number of subjects: 27
Study 2270581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7448347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 0
Study 7448347 — intervention group
Group type: COMPARATOR
Intervention: Capsules
Number of subjects: 0
Study 31465810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score label applied to snacks
Number of subjects: 95
Study 28249614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with sufentanil
Number of subjects: 97
Study 28249614 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil alone (control group)
Number of subjects: 97
Study 27765058 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized sensorimotor exercise program (12 weeks: 3 weeks supervised centre-based and 9 weeks home-based)
Number of subjects: 0
Study 27765058 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 0
Study 22582349 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 30
Study 22582349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22275471 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 79
Study 22275471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 19883809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin (group A)
Number of subjects: 40
Study 19883809 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40
Study 17518959 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic tongue press exercise
Number of subjects: 53
Study 17518959 — intervention group
Group type: COMPARATOR
Intervention: Isometric tongue press exercise
Number of subjects: 53
Study 17518959 — intervention group
Group type: COMPARATOR
Intervention: Isotonic head lift exercise
Number of subjects: 53
Study 15470307 — intervention group
Group type: EXPERIMENTAL
Intervention: Long rest interval (160 s rest period)
Number of subjects: 15
Study 15470307 — intervention group
Group type: EXPERIMENTAL
Intervention: Short rest interval (40 s rest period)
Number of subjects: 15
Study 15470307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study 11477461 — intervention group
Group type: EXPERIMENTAL
Intervention: High group (500 g/day fruit and vegetables and 200 ml/day fruit juice)
Number of subjects: 48
Study 11477461 — intervention group
Group type: COMPARATOR
Intervention: Low group (100 g/day fruit and vegetables)
Number of subjects: 48
Study 9700713 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 42
Study 9700713 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study 8206395 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (single injection)
Number of subjects: 11
Study 8206395 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms/day subcutaneously for three weeks)
Number of subjects: 11
Study 8206395 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (100 micrograms/day subcutaneously)
Number of subjects: 11
Study 8206395 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide in irritable bowel syndrome patients
Number of subjects: 11
Study 2913770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13
Study 2913770 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 4601984 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, CCNU
Number of subjects: 80
Study 4601984 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC
Number of subjects: 80
Study 4601984 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC and BCNU
Number of subjects: 80
Study 4601984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG
Number of subjects: 80
Study 31563344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (3 g intravenously every 8 h for 8-14 days)
Number of subjects: 726
Study 31563344 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g intravenously every 8 h for 8-14 days)
Number of subjects: 726
Study 31563344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 726
Study 31563344 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 726
Study 29018022 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 16791
Study 29018022 — intervention group
Group type: COMPARATOR
Intervention: Obesity in men
Number of subjects: 16791
Study 29018022 — intervention group
Group type: COMPARATOR
Intervention: Obesity in women
Number of subjects: 16791
Study 26307616 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based Pulmonary Rehabilitation programme
Number of subjects: 0
Study 26307616 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pulmonary Rehabilitation programme
Number of subjects: 0
Study 23660721 — intervention group
Group type: COMPARATOR
Intervention: Control group without additional training (group 1)
Number of subjects: 39
Study 23660721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass training group with one supervised training session (150 min) after 2.5 months (group 2)
Number of subjects: 39
Study 23660721 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed training group with five monthly unsupervised training sessions of 30 min on a box trainer (group 3)
Number of subjects: 39
Study 23660721 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed training group with five monthly unsupervised training sessions of 30 min on the LapMentor(®) (group 4)
Number of subjects: 39
Study 23660721 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine Nissen model
Number of subjects: 39
Study 22057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus photodynamic therapy (Sc/Rp + PDT)
Number of subjects: 20
Study 22057609 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only (Sc/Rp)
Number of subjects: 20
Study 18845008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive Behavioral Therapy (CBT)
Number of subjects: 93